We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Screening Blood Supply for Murine Viruses Is Superfluous

By LabMedica International staff writers
Posted on 11 Oct 2011
The validity of testing techniques intended to detect the presence of several viruses in blood donated for transfusion has been examined. More...


Murine leukemia viruses (MLV), including xenotropic-MLV-related virus (XMRV), and the related polytrophic murine leukemia viruses (P-MLVs) were looked for in blood samples of healthy donors who were previously known to not have the viruses.

In a recent study, blood samples were taken from healthy donors and from 14 patients with chronic fatigue syndrome (CFS) who had previously tested positive for XMRV or P-MLV, and samples from another person who had tested positive for XMRV but who did not have CFS. The study also used blood samples from healthy volunteers whose blood tests previously had shown no signs of XMRV/P-MLV. The scientists used 11 nucleic acid, five antibody, and three culture assays to determine the assays’ abilities to detect XMRV/P-MLVs. The study also checked for evidence of contamination with mouse DNA, because XMRV or its predecessors may be present in some mouse strains and cell lines. The MLV have been controversially linked to CFS.

The samples were blinded with no indication as to their source, and sent to nine laboratories. The study involved laboratories supported by several US governmental agencies along with Abbott Laboratories (Abbott Park, IL, USA), GenProbe, Inc. (San Diego, CA, USA), and the Whittemore Peterson Institute (WPI; Reno, NV, USA). The laboratories reported similar rates of finding XMRV in samples from patients with chronic fatigue syndrome and from healthy donors who were known to not have XMRV. Additional tests run in the same and other laboratories on the same samples did not find XMRV, strongly suggesting that these persons were negative for XMRV/P-MLVs. This would be a sign that the few observed positive results represented false-positives, which means the results indicated the condition was present when it actually was not.

Susan B. Shurin, MD, from the US National Institutes of Health (Bethesda, MD, USA), said, “The results of this study, along with other recent findings, reassure us that these viruses do not pose a threat to the safety of the nation’s blood supply. These data add to the mounting evidence that there is no need to screen blood donors for them at the present time.”

The report was published on September 22, 2011, in the journal Science Express.

Related Links:
Abbott Laboratories
GenProbe
US National Institutes of Health


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.